DK1326609T3 - Stabil, oral formulering, der indeholder benzimidazolderivat - Google Patents

Stabil, oral formulering, der indeholder benzimidazolderivat

Info

Publication number
DK1326609T3
DK1326609T3 DK01978022T DK01978022T DK1326609T3 DK 1326609 T3 DK1326609 T3 DK 1326609T3 DK 01978022 T DK01978022 T DK 01978022T DK 01978022 T DK01978022 T DK 01978022T DK 1326609 T3 DK1326609 T3 DK 1326609T3
Authority
DK
Denmark
Prior art keywords
formulation containing
oral formulation
benzimidazole derivative
stable oral
containing benzimidazole
Prior art date
Application number
DK01978022T
Other languages
English (en)
Inventor
Arthur Deboeck
Francis Vanderbist
Antonio Sereno
Philippe Baudier
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar M F filed Critical Galephar M F
Application granted granted Critical
Publication of DK1326609T3 publication Critical patent/DK1326609T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01978022T 2000-10-20 2001-10-18 Stabil, oral formulering, der indeholder benzimidazolderivat DK1326609T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BE2000/000126 WO2002032427A1 (en) 2000-10-20 2000-10-20 Stable oral formulation containing benzimidazole derivative

Publications (1)

Publication Number Publication Date
DK1326609T3 true DK1326609T3 (da) 2006-01-02

Family

ID=3862554

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01978022T DK1326609T3 (da) 2000-10-20 2001-10-18 Stabil, oral formulering, der indeholder benzimidazolderivat

Country Status (8)

Country Link
US (3) US20040043069A1 (da)
EP (1) EP1326609B1 (da)
AT (1) ATE302004T1 (da)
AU (3) AU2001211213A1 (da)
CA (1) CA2426175A1 (da)
DE (1) DE60112781T2 (da)
DK (1) DK1326609T3 (da)
WO (2) WO2002032427A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
CA2787568C (en) 2010-01-28 2019-04-02 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
BR112012022775A2 (pt) * 2010-03-10 2016-07-19 Nogra Pharma Ltd composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas
PL3533447T3 (pl) 2012-03-20 2023-07-17 Eagle Pharmaceuticals, Inc. Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
CN104302291A (zh) 2012-03-20 2015-01-21 鹰制药股份有限公司 苯达莫司汀的制剂
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN113384547B (zh) * 2021-06-25 2024-03-19 上海信谊万象药业股份有限公司 一种奥美拉唑铝碳酸镁复合片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19918434A1 (de) * 1999-04-23 2000-10-26 Basf Ag Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Also Published As

Publication number Publication date
US20080311204A1 (en) 2008-12-18
DE60112781T2 (de) 2006-05-18
AU2002210284B2 (en) 2006-11-16
AU2001211213A1 (en) 2002-04-29
CA2426175A1 (en) 2002-04-25
DE60112781D1 (de) 2005-09-22
WO2002032425A3 (en) 2003-01-16
WO2002032427A1 (en) 2002-04-25
WO2002032425A2 (en) 2002-04-25
ATE302004T1 (de) 2005-09-15
EP1326609A2 (en) 2003-07-16
US20070196486A1 (en) 2007-08-23
AU1028402A (en) 2002-04-29
EP1326609B1 (en) 2005-08-17
US20040043069A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
DK1326609T3 (da) Stabil, oral formulering, der indeholder benzimidazolderivat
RS49673B (sr) Inhibitori sintaze azot-monoksida
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK0381446T3 (da) Orale anti-svampepræparater
PT1193270E (pt) Pirrolobenzodiazepinas
CY1107634T1 (el) Φαρμακευτικη συνθεση
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
BR0307158A (pt) Goma de mascar recheada contendo cálcio
HRP20030383B1 (en) Lactam compound
TR200102490T2 (tr) Fenil ve piridinil türevleri
BR0109943A (pt) Composições farmacêuticas
ATE322485T1 (de) Propan-1,3-dion-derivate
NO20034660L (no) Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater
TR200301723T4 (tr) 1,3 Dihidro-2H-indol-2 one türevleri ve bunların, arginin-vasopressin' in V1B veya V1B reseptörleri için bağ maddeleri olarak kullanımı
SE0004245D0 (sv) Novel compounds and their use
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
HUP9700654A2 (hu) Teobromin tartalmú köhögéscsillapító készítmények
RS50229B (sr) Analozi vitamina d3
ATE255105T1 (de) Serotonerge benzofurane
TR200000419T2 (tr) Feksofenadin ve türevlerinin biyo elde edilebilirliklerinin arttırılması yöntemi.
BRPI0411218A (pt) formulações alvejantes fluorescentes estáveis em estocagem
TR199901209T2 (xx) B�cek �ld�r�c� ve mitisidal kompozisyonlar
DK1106174T3 (da) Sammensætninger der indeholder fedtoplöselige vitaminer
TR199901374T2 (xx) B�cek �ld�r�c� ve mitisidal kompozisyonlar